Brentuximab vedotin in refractory CD30+ lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK Centre

A Gibb, C Jones, A Bloor, S Kulkarni, T Illidge, K Linton, J Radford

    Research output: Contribution to journalArticlepeer-review

    Original languageEnglish
    Publication statusPublished - Oct 2012

    Cite this